Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AV 203

Drug Profile

AV 203

Alternative Names: AV-203; CAN-017

Latest Information Update: 18 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AVEO Pharmaceuticals
  • Developer AVEO Oncology; CANbridge Life Sciences
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action ERBB-3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Oesophageal cancer
  • No development reported Solid tumours

Most Recent Events

  • 14 Aug 2018 CANbridge Life Sciences plans a phase Ib/III trial for Oesophageal cancer (Late stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in China in 2018
  • 14 Aug 2018 Preclinical trials in Oesophageal cancer in China (IV)
  • 14 Aug 2018 China National Drug Administration (CNDA) accepts IND application for AV 203 in Oesophaeal cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top